Novartis Pharmaceuticals announced that the U.S. Food and Drug Administration (FDA) has approved it's new drug, Beovu¬Æ, for the treatment of wet age-related macular degeneration (AMD).
Beovu¬Æ (brolucizumab) recently completed two late-stage clinical trials, which tested the safety and efficacy of the intravitreal injection. Wet AMD is an eye condition which can lead to a complete loss of central vision that is expected to affect 1.75 million Americans over the next year and is currently treated using monthly intravitreal injections of either Eylea¬Æ or Lucentis¬Æ.
In clinical trials, Beovu¬Æ demonstrated greater fluid reduction in patients as well as an improvement in vision when compared to current therapies. Beovu¬Æ also has the potential to treat some patients with either quarterly injections, or every other month injections compared to the current therapies that are given on a monthly basis.
The pricing of the new drug will be $1850 per vial which is the same price point of Eylea¬Æ while Lucentis¬Æ runs $2,000 per vial. Currently, Novartis does not have a planned date of when the drug will be made available.*